Opinion|Videos|January 3, 2025
Empowering Patients in Treatment Planning
Author(s)David Dingli, MD, PhD, Brandi Lewis
Panelists discuss resources and strategies to help patients and caregivers cope with the initial shock of a paroxysmal nocturnal hemoglobinuria (PNH) diagnosis, emphasizing critical points during the first consultation, and explore how Brandi communicated her treatment preferences to her care team, reflecting on her sense of inclusion in the decision-making process and areas for improvement.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What resources or strategies do you recommend helping patients and caregivers overcome the initial shock of a PNH diagnosis?
- What are the most critical points you emphasize to patients and caregivers during the first consultation?
- When deciding on a treatment plan, what factors were most important to you, and how did you communicate that to your care team?
- Did you feel included in the decision-making process? What worked well, and what could have been improved?
This program was made possible with support from Novartis Pharmaceuticals.
Advertisement
Related to this article
The FDA granted platform technology designation to the immunotherapeutic platform for use in HPV-positive cancers such as head and neck, cervical, and anal.
An end-of-phase 1 meeting was supported by phase 1b data showing efficacy with LYT-220 among relapsed/refractory myelodysplastic syndrome groups.
Beth Erickson, MD, FACR, FASTRO, FABS, discussed pioneering MRI-guided brachytherapy at MCW and her priorities as incoming ASTRO president-elect.
The updated NCCN Guidelines for myeloproliferative neoplasms recommend rusfertide as a category 1 option across both low- and high-risk polycythemia vera.
As part of the ANDA pathway, Bravnetsa is the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to the reference product, Lutathera.
Xiuning Le, MD, PhD, explains how oncologists should approach HER2 biomarker testing following sevabertinib’s frontline approval in non–small cell lung cancer.
Peter Forsyth, MD, discusses a first-in-human trial of intrathecal dendritic cell therapy for leptomeningeal disease from breast cancer.
Adding radiotherapy to tislelizumab and chemotherapy also appeared to prolong progression-free survival in a real-world setting.
Advertisement
Advertisement
Trending on CancerNetwork
1
Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer
2
Lutetium Lu 177 Dotatate Biosimilar Earns Final FDA Approval in GEP-NETs
3
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
4
COA Warns That Price Negotiation for Medicare Part B Drugs Threatens Community Oncology
5